After a series of stops and starts, French live music association Prodiss and Paris hospital AP-HP have finally been given the green light for the Paris test concert.
The clinical trial was initially announced in February and should have taken place in April but the scheme got “stuck on the government side”, with the ministry of culture proving “unreachable” amid the new lockdown measures.
The experiment, dubbed ‘Ambition Live Again’, will now take place on 29 May at the Accor Arena (20,300-cap.) in Paris with DJ Etienne de Crécy and the band Indochine.
The trial will compare the risk of contamination between two randomised groups: an experimental group of 5,000 people will attend the concert and a control group of 2,500 people will not attend the concert.
The trial will compare the risk of contamination between two randomised groups
The concertgoers will be required to take an antigen test a maximum of 72 hours before the concert and a PCR test seven days after the concert, while the control group will take a self-test on the day of the concert.
Once inside, attendees will not socially distance, though everyone will be required to wear a mask.
The scientific team specified that the participants could not be people at risk and must be in an age group between 18-45 years old and live in Ile-de-France. A full list of criteria can be found on the Ambition Live Again website.
The sister pilot in Marseille was also hit by delays and has not yet been rescheduled. As reported in IQ, a thousand people are expected to attend the two shows at the Dôme (cap. 8,500) in Marseille, which will see performances from French hip-hop group Iam.
See IQ‘s extensive timeline of live music pilot projects here and read about them in-depth here.
Get more stories like this in your inbox by signing up for IQ Index, IQ’s free email digest of essential live music industry news.